Carbon monoxide poisoning

Overview

Carbon monoxide (CO) poisoning is the leading cause of death in victims of fire-related inhalation injury ^[1][7]. CO is a colorless, odorless gas produced by incomplete combustion. It binds hemoglobin with 200 to 250 times the affinity of oxygen, forming carboxyhemoglobin (COHb) and reducing oxygen-carrying capacity. CO also binds myoglobin and mitochondrial cytochrome oxidase, directly impairing cellular respiration ^[1][2][4].

In the burned patient, CO poisoning frequently coexists with cyanide toxicity and direct airway thermal or chemical injury, creating a complex presentation requiring simultaneous evaluation and treatment ^[4]. Standard pulse oximetry cannot distinguish COHb from oxyhemoglobin, making clinical suspicion and co-oximetry essential for diagnosis ^[3].

Pathophysiology

CO exerts toxicity through multiple mechanisms ^[1][2][4]:

• Hemoglobin binding: CO displaces oxygen from hemoglobin, shifting the oxyhemoglobin dissociation curve leftward and further impairing oxygen release to tissues.
• Myoglobin binding: CO binds cardiac myoglobin, contributing to myocardial depression and arrhythmias.
• Mitochondrial toxicity: CO inhibits cytochrome c oxidase in the mitochondrial electron transport chain, directly impeding aerobic metabolism.
• Inflammatory cascade: CO triggers lipid peroxidation, leukocyte-mediated oxidative stress, and delayed neurologic injury through inflammatory mechanisms in the central nervous system.

The half-life of COHb is approximately 5 hours breathing room air, 60 to 90 minutes on 100% normobaric oxygen, and approximately 20 minutes under hyperbaric conditions ^[3].

Clinical Presentation

Symptoms correlate roughly with COHb levels, though individual variation is significant ^[1][7]:

• COHb 10-20%: headache, nausea, dizziness, confusion
• COHb 20-40%: visual disturbances, syncope, tachycardia, chest pain
• COHb 40-60%: seizures, coma, cardiovascular collapse
• COHb >60%: frequently fatal

The classic "cherry red" skin discoloration is rarely observed clinically. Arterial blood gas PaO2 may be normal because dissolved oxygen is unaffected; diagnosis requires co-oximetry to measure COHb directly ^[1].

Diagnosis

Diagnosis rests on clinical suspicion in the setting of enclosed-space fire exposure, altered mental status, or cardiovascular compromise ^[7]. Key diagnostic steps include:

• Co-oximetry: Measures COHb level directly. Standard pulse oximetry is unreliable.
• Arterial blood gas: PaO2 may be normal; calculated oxygen saturation is falsely reassuring. The measured SaO2 on co-oximetry reveals the true deficit.
• Lactate: Elevated serum lactate reflects tissue hypoxia and may indicate concurrent cyanide toxicity ^[4].
• ECG: Cardiac monitoring for ischemia and arrhythmias, particularly in patients with pre-existing cardiac disease.

COHb levels at presentation may underestimate peak exposure, particularly if the patient has received supplemental oxygen during transport ^[1].

Treatment

The primary treatment for CO poisoning is displacement of CO from hemoglobin by maximizing the oxygen partial pressure gradient ^[1][3]:

• 100% normobaric oxygen (NBO): Standard first-line treatment. Reduces COHb half-life to 60-90 minutes. Administered via non-rebreather mask or, in intubated patients, via ventilator at FiO2 1.0. Continue until COHb falls below 5% and neurologic symptoms resolve.
• Hyperbaric oxygen (HBO): Reduces COHb half-life to approximately 20 minutes. The primary proposed benefit is reduction of delayed neurologic sequelae.

Hyperbaric Oxygen Controversy

The role of HBO in CO poisoning remains one of the most debated topics in burn and toxicology care. Six prospective randomized trials have been conducted; Hampson et al. systematically reviewed all six and concluded that the best-designed trial supports HBO efficacy ^[9].

The largest and most rigorously designed randomized trial, conducted by Weaver et al. in 2002, found that three HBO treatments within 24 hours reduced cognitive sequelae at 6 weeks from 46% to 25% (P=0.007) and the benefit persisted at 12 months ^[8]. This trial is the primary evidence supporting HBO use. However, methodological criticisms, including questions about blinding adequacy and the clinical significance of neuropsychological test differences, have prevented universal consensus ^[5][9].

A 2023 review found that while HBO accelerates CO elimination, evidence supporting its routine use for preventing delayed neurologic sequelae is inconsistent across the full body of trials ^[5]. Challenges include heterogeneous study populations, variable treatment protocols, and difficulty blinding in RCTs. The Tenth European Consensus Conference on Hyperbaric Medicine (2016) classified CO poisoning as a Type 1 recommendation for HBO, but acknowledged the need for larger trials ^[5][6]. The ATS practice recommendations emphasize that treatment decisions should weigh severity of poisoning, time to treatment, and local HBO availability ^[10].

In the burned pregnant patient, fetal hemoglobin binds CO 2.5 to 3 times more avidly than maternal hemoglobin, and fetal CO elimination is markedly slower. This population has a stronger indication for HBO ^[3].

Special Considerations in Burn Patients

CO poisoning in burn patients presents unique challenges:

• Concurrent cyanide toxicity: CO and cyanide act synergistically, lowering the lethal threshold for both toxins. Empiric hydroxocobalamin administration should be considered in all patients with enclosed-space fire exposure and altered mental status ^[3][4].
• Fluid resuscitation: Transfer to a hyperbaric facility may delay burn resuscitation in large burns. The risk-benefit calculation must weigh burn size, resuscitation needs, and severity of CO exposure.
• Pulse oximetry unreliability: Standard pulse oximetry reads falsely normal in the presence of COHb. Co-oximetry is required until COHb clears ^[1].

Controversies and Evidence Gaps

• The threshold COHb level for initiating HBO therapy is not standardized. Proposed thresholds range from 25% to 40%, with additional criteria including loss of consciousness, pregnancy, and cardiac ischemia ^[5][6][10].
• No large RCT has evaluated HBO specifically in burn patients with concurrent CO poisoning and cutaneous injury ^[6].
• The contribution of delayed neurologic sequelae in burn patients who survive CO exposure is poorly characterized, as neuropsychiatric outcomes are confounded by critical illness, sedation, and prolonged ICU stay ^[5].
• Optimal duration of NBO therapy after COHb normalization is undefined VERIFY.

References

[1] Foncerrada G et al. "Inhalation Injury in the Burned Patient." Ann Plast Surg 2018;80(3 Suppl 2):S98-S105. PMID: 29461292. [2] Ernst A, Zibrak JD. "Carbon monoxide poisoning." N Engl J Med 1998;339:1603-8. PMID: 9828249. [3] Culnan DM et al. "Carbon Monoxide and Cyanide Poisoning in the Burned Pregnant Patient: An Indication for Hyperbaric Oxygen Therapy." Ann Plast Surg 2018;80(3 Suppl 2):S106-S112. PMID: 29461288. [4] Huzar TF et al. "Carbon monoxide and cyanide toxicity: etiology, pathophysiology and treatment in inhalation injury." Expert Rev Respir Med 2013;7(2):159-70. PMID: 23547992. [5] Freytag DL et al. "Hyperbaric oxygen treatment in carbon monoxide poisoning - Does it really matter?" Burns 2023;49(8):1783-1787. PMID: 37821285. [6] Weitgasser L et al. "Update on hyperbaric oxygen therapy in burn treatment." Wien Klin Wochenschr 2019;133(3-4):137-143. PMID: 31701218. [7] Heimbach DM, Waeckerle JF. "Inhalation injuries." Ann Emerg Med 1988;17(12):1316-20. PMID: 3057948. [8] Weaver LK et al. "Hyperbaric oxygen for acute carbon monoxide poisoning." N Engl J Med 2002;347:1057-67. PMID: 12362006. [9] Hampson NB et al. "Carbon monoxide poisoning: interpretation of randomized clinical trials and unresolved treatment issues." Undersea Hyperb Med 2001;28:157-64. PMID: 12067152. [10] Hampson NB, Piantadosi CA, Thom SR, Weaver LK. "Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning." Am J Respir Crit Care Med 2012;186:1095-101. PMID: 23087025.